Warning letter
AstraZeneca AB: warning letter of Nov 9, 2001
FDA warning letter UCM178853 · Center for Devices and Radiological Health
Key facts
| Reference number | UCM178853 |
|---|---|
| Company | AstraZeneca AB |
| Subject | Deviations from CGMP for Finished Pharmaceuticals |
| Issue date | Nov 9, 2001 |
| Posted date | Nov 9, 2001 |
| Issuing office | Center for Devices and Radiological Health |
| Product type | Drugs |
| Country | 3 |
| Inspection city | Sodertalje |
| Inspection start date | May 7, 2001 |
| Letter on fda.gov | web.archive.org |
At a glance
- OAI Linked inspection classification
- Yes Form FDA 483 issued
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA warning letters
FDA warning letters notify a firm of significant regulatory violations found during an inspection or review and request prompt corrective action.
Source: U.S. Food and Drug Administration (FDA), Warning Letters · Source date: